Journal
INTERNATIONAL IMMUNOLOGY
Volume 33, Issue 10, Pages 515-519Publisher
OXFORD UNIV PRESS
DOI: 10.1093/intimm/dxab011
Keywords
cytokine release syndrome; cytokine storm; tocilizumab
Categories
Funding
- Kishimoto Foundation
Ask authors/readers for more resources
Tocilizumab, an anti-IL-6 receptor antibody, has been effective in treating chronic autoimmune inflammatory diseases and alleviating cytokine storms induced by CAR-T-cell therapy. It is also considered a potential therapeutic for serious cases of COVID-19 with cytokine release syndrome.
Blockade of IL-6 function by an anti-IL-6 receptor (IL-6R) antibody (tocilizumab, trade name Actemra) has been shown to be effective for the treatment of chronic autoimmune inflammatory diseases including rheumatoid arthritis. Interestingly, treatment with tocilizumab has also been found to alleviate the cytokine storm induced by chimeric antigen receptor (CAR)-T-cell therapy. Patients with serious cases of coronavirus disease 2019 (COVID-19) exhibit cytokine release syndrome (CRS), which suggested that tocilizumab might be an effective therapeutic for serious cases of COVID-19. In the first part of this short review, the therapeutic effect of tocilizumab for the disease induced by IL-6 overproduction is described. CRS induced by CAR-T-cell therapy and COVID-19 is then discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available